# Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched | This GLP

Do GLP-1 drugs help resistant hypertension? A 4,153-per-arm matched cohort found the same pressure fall as an MRA | and mortality at HR 0.34, which is not credible.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension
Updated: 2026-09-18
Published: 2026-09-17

[← Research](https://thisglp.com/research)

Evidence

# Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched

Two fourth-line drugs lowered blood pressure by the same amount. One group then had a two-thirds lower risk of dying, which is a fact about who gets which drug rather than about the drug. No randomized trial has reported an outcome in this population.

[This GLP Editorial Team](https://thisglp.com/about)September 20269 min read

Systolic blood pressure change at 12 weeks · GLP-1 · −5.7 mmHg · MRA · −6.3 mmHg · All-cause mortality, same two groups · hazard ratio 0.34 — a two-thirds difference · The treated quantity matched. The outcomes did not.

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).

No randomized trial has tested one for it. The evidence is a matched cohort of 4,153 patients per arm, and it found what a trial would not [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-1). Blood pressure fell 5.7 mmHg on a GLP-1 against 6.3 mmHg on a mineralocorticoid receptor antagonist. On the thing both drugs were prescribed to do, the two groups landed in the same place. Everything afterward differed: MACE at HR 0.63, kidney events at 0.64, all-cause mortality at 0.34. A two-thirds reduction in death with the treated quantity equalized is a signature of confounding.

## Key takeaways

-   A matched cohort compared GLP-1 drugs against mineralocorticoid receptor antagonists as fourth-line therapy for resistant hypertension.
-   After matching, 4,153 patients remained in each group, followed a median of 1.4 years.
-   Blood pressure fell by a similar amount in both: −5.7 mmHg against −6.3 mmHg at 12 weeks.
-   Outcomes did not match: MACE HR 0.63, kidney events HR 0.64, and all-cause mortality HR 0.34.
-   A Cochrane review found the semaglutide and tirzepatide trials in hypertension reported no mortality or cardiovascular results at all.

Resistant hypertension means pressure still uncontrolled on three drugs at once. It is a specific diagnosis, not a description of a bad reading. The question here is whether a GLP-1 belongs as the fourth drug, and the general blood-pressure and vascular evidence is a different matter, set out in [the vessel-function measurements](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function).

## What was compared

Adults with overweight or obesity and resistant hypertension, across 67 US healthcare organizations, who started a fourth drug between 2017 and 2025 [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-1). Those starting semaglutide or tirzepatide were matched against those starting spironolactone or eplerenone, the guideline-recommended option. Of 213,309 eligible patients, 22,694 started a GLP-1 and 5,673 an MRA. Propensity matching left 4,153 in each group.

Over a median 1.4 years the GLP-1 group had lower risks across the board. MACE HR 0.63, 95% CI 0.52 to 0.78. Cardiovascular events HR 0.74, 95% CI 0.59 to 0.92. Major adverse kidney events HR 0.64, 95% CI 0.46 to 0.88. Acute kidney injury HR 0.62, 95% CI 0.46 to 0.83. All-cause mortality HR 0.34, 95% CI 0.21 to 0.55.

## And the blood pressure

Systolic pressure fell 5.7 mmHg on the GLP-1 and 6.3 mmHg on the MRA at twelve weeks, with overlapping intervals. On the thing both drugs were prescribed to do, the two groups were the same. The MRA arm did marginally better.

The study undermines its own headline

If GLP-1 therapy produced better cardiovascular and kidney outcomes because it controlled pressure better, the pressure data would show it. They do not. Something other than the treated quantity is separating these two groups, and a 66% lower risk of death from any cause over 1.4 years is far larger than any plausible pharmacological explanation for it.

Consider what it takes to be in each group. Spironolactone is a decades-old generic costing a few dollars a month. A clinician can add it this afternoon. Getting semaglutide or tirzepatide approved as a fourth-line blood pressure drug takes an insurer’s cooperation, a prescriber willing to pursue it, documentation, and often the patient’s own money.

The people who clear that are better insured, more engaged with their care, and well enough to be considered for an elective addition. Those characteristics predict survival on their own. Propensity matching adjusts for what was recorded, and none of that is recorded. It is the same shape of confounding visible from the access side in [the uptake registry](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke).

## What the trials reported, which is nothing

A Cochrane review now in its fourth update pooled eight randomized trials of long-term weight drugs in adults with hypertension, about 13,000 participants [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-2). For both semaglutide and tirzepatide it records that no results were reported for all-cause mortality, cardiovascular morbidity, serious adverse events or adverse events. Liraglutide could not be entered at all, because no trial has published separate figures for hypertensive participants.

That is not a safety finding. It says the trials did not report the outcomes a reviewer needs, in a population where the question is unusually live. The older drugs did report. Orlistat probably increases serious adverse events at RR 1.45, 95% CI 1.10 to 1.91, across three trials and 1,476 participants. The full reading is in [the Cochrane update](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths).

## What the randomized evidence does support

In broader populations the hard outcomes are real and much smaller than the cohort suggests. A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87, 95% CI 0.81 to 0.93, alongside kidney benefits [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-3). That is a 13% relative reduction, not a 37% one, and it comes from randomization rather than from matching. Stroke measured on its own is thinner still, as [the stroke evidence](https://thisglp.com/research/do-glp1-drugs-prevent-stroke) sets out.

So the practical position is narrow. A GLP-1 achieved about the same pressure reduction as the guideline drug in a population where pressure is hard to move. The outcome gap beside it is not credible at the size reported. The authors say prospective studies are needed to determine whether these drugs should be part of treatment for resistant hypertension, and that is the correct conclusion from their own data.

Nobody on this roster sells anything for resistant hypertension. What sellers publish about who they will and will not prescribe to is thin. [The ordinary-care results](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) show what happens to trial figures once access decides who is in the sample.

## Frequently asked

Do GLP-1 drugs help resistant hypertension?

They lowered systolic pressure by 5.7 mmHg, about the same as the guideline fourth-line drug at 6.3 mmHg. No randomized trial has tested one in this population for any hard outcome.

Why distrust the mortality result?

All-cause mortality came out at HR 0.34 while both groups reached the same blood pressure. If the drug worked through pressure, the pressure data would show it. A two-thirds reduction in death over 1.4 years is larger than randomized evidence supports.

What did the randomized trials report?

In hypertension, nothing. A Cochrane review records that the semaglutide and tirzepatide trials reported no results for mortality, cardiovascular morbidity or adverse events.

What is the credible size of the cardiovascular benefit?

A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87, 95% CI 0.81 to 0.93 — a 13% relative reduction in broader populations, not the 37% the cohort reports.

## Sources

1.  \[1\] Tian Z, et al. (2026). Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA eClinicalMedicine. [PMID 42701458](https://pubmed.ncbi.nlm.nih.gov/42701458/)
2.  \[2\] Spary-Kainz U, Posch N, Radl-Karimi C, Jeitler K, Krenn C, Siebenhofer A (2026). Long-term effects of weight-reducing drugs in people with hypertension Cochrane Database of Systematic Reviews. [PMID 42318855](https://pubmed.ncbi.nlm.nih.gov/42318855/)
3.  \[3\] Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials The Lancet Diabetes & Endocrinology. [PMID 39608381](https://pubmed.ncbi.nlm.nih.gov/39608381/)

## Where to get it

### Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

[Compare providers →](https://thisglp.com/best/compounded-semaglutide)

## More in Evidence

-   [
    
    150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability
    
    ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms
    
    ](https://thisglp.com/research/exercise-on-ozempic)
-   [
    
    STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower.
    
    ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show
    
    ](https://thisglp.com/research/does-ozempic-lower-cholesterol)
-   [
    
    Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight.
    
    ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found
    
    ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)